- Cardiovascular Diseases
- Diabetes
- Cancer
- Neurological Disorders
- Gastrointestinal Diseases
- Dermatology Diseases
- Others
Branded Generics In Emerging Market size was valued at USD 286.4 Billion in 2023 and is anticipated to grow at a CAGR of 7.1 % from 2024-2030. Branded generics, also known as "branded off-patent" or "branded generic drugs," are a category of pharmaceutical products that fall between traditional brand-name (innovator) drugs and unbranded generics. Branded generics, which are generic drugs endowed with a proprietary market name, are promoted in a manner reminiscent of branded drugs. In contrast to conventional generics identified by their chemical names, branded generics receive names aimed at enhancing recognition and fostering consumer allegiance. These named generics can be created by generic drug manufacturers or even by the original developers and undergo the same FDA approval process as other generic medications post-patent of branded drug expiry. Quality perception and trust play a pivotal role in driving the growth of the branded generics market in emerging countries. In these regions, consumers often associate brand names with higher quality and reliability, creating a foundation of trust. This dynamic becomes a catalyst for the adoption of branded generics, as pharmaceutical companies leverage established brand names to build credibility for their generic offerings. By aligning generics with well-known brands, consumers are more likely to view these products as safe and effective alternatives to expensive brand-name drugs.
Moreover, pricing strategies significantly drive the revenues of the branded generics market in emerging countries. In these regions, where affordability is a significant consideration for consumers, pharmaceutical companies strategically position branded generics as a cost-effective alternative to brand-name drugs. By pricing branded generics slightly higher than unbranded generics but still significantly lower than their brand-name counterparts, companies create a pricing tier that appeals to a broad range of consumers. However, emerging markets often have diverse and evolving regulatory landscapes. Navigating complex registration and approval processes for branded generics can be challenging, leading to delays in market entry and increased compliance costs. This acts as a significant restraint to the market growth. Meanwhile, the growing middle-class population with increasing disposable incomes offers significant opportunities for the growth of the branded generic drugs market in emerging countries like Brazil, Russia, India, and China.
Study Period
2024-2030Base Year
2023CAGR
6.3%Largest Market
Asia-pacificFastest Growing Market
Latin America
Rise in out-of-pocket healthcare expenditure and vast market opportunities expected to drive market revenue growth significantly. The healthcare spending as % of total private healthcare expenditure is high in major countries such as India, China, and Brazil, which is likely to impact market growth positively over the forecast period. For instance in 2014, According to World Bank global health expenditure database, Out-of-pocket health expenditure (% of private expenditure on health) in India and China were 89.2% and 72.3% respectively. Moreover, several countries in emerging markets witnessing growing middle-class and rise in incomes, which is expected to create significant demand for branded generics in the emerging countries. In addition, emerging countries account for more than 50% of branded generics sales across the globe, this helps the multinational and local pharmaceutical companies to capitalize the ever-growing market opportunities in the region.
By Diseases Indication
By Route-administration
By Distribution Channel
The branded generics in emerging market size was valued at USD 286.4 billion in 2023
The branded generics in emerging market key players are: Abbott Laboratories (U.S.) Apotex Inc. (Canada) AstraZeneca (U.K) CSPC Pharmaceutical Group Limited. (China) Reddys Laboratories Ltd. (India) GlaxoSmithKline plc (U.K) Mylan N.V. (U.S.) Novartis AG (Switzerland) Pfizer Inc. (U.S) Sanofi (France) Sun Pharmaceutical Industries Ltd. (India) Teva Pharmaceutical Industries Ltd (Israel) Valeant Pharmaceuticals International, Inc. (Canada) Nichi-Iko Pharmaceutical Co., Ltd ( Japan)
The branded generics in emerging market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
1. Executive Summary |
2. Global Branded Generics In Emerging Market Introduction |
2.1.Global Branded Generics In Emerging Market - Taxonomy |
2.2.Global Branded Generics In Emerging Market - Definitions |
2.2.1.Diseases Indication |
2.2.2.Route-administration |
2.2.3.Distribution Channel |
2.2.4.Region |
3. Global Branded Generics In Emerging Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Branded Generics In Emerging Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Branded Generics In Emerging Market By Diseases Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Cardiovascular Diseases |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Diabetes |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Cancer |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Neurological Disorders |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Gastrointestinal Diseases |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Dermatology Diseases |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Others |
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
6. Global Branded Generics In Emerging Market By Route-administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Oral |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Parenteral |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Topical |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Others |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7. Global Branded Generics In Emerging Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Drug Stores |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Online Pharmacies |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8. Global Branded Generics In Emerging Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9. North America Branded Generics In Emerging Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Diseases Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Cardiovascular Diseases |
9.1.2.Diabetes |
9.1.3.Cancer |
9.1.4.Neurological Disorders |
9.1.5.Gastrointestinal Diseases |
9.1.6.Dermatology Diseases |
9.1.7.Others |
9.2. Route-administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oral |
9.2.2.Parenteral |
9.2.3.Topical |
9.2.4.Others |
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Drug Stores |
9.3.4.Online Pharmacies |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10. Europe Branded Generics In Emerging Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Diseases Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Cardiovascular Diseases |
10.1.2.Diabetes |
10.1.3.Cancer |
10.1.4.Neurological Disorders |
10.1.5.Gastrointestinal Diseases |
10.1.6.Dermatology Diseases |
10.1.7.Others |
10.2. Route-administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oral |
10.2.2.Parenteral |
10.2.3.Topical |
10.2.4.Others |
10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Drug Stores |
10.3.4.Online Pharmacies |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
11. Asia Pacific (APAC) Branded Generics In Emerging Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Diseases Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Cardiovascular Diseases |
11.1.2.Diabetes |
11.1.3.Cancer |
11.1.4.Neurological Disorders |
11.1.5.Gastrointestinal Diseases |
11.1.6.Dermatology Diseases |
11.1.7.Others |
11.2. Route-administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oral |
11.2.2.Parenteral |
11.2.3.Topical |
11.2.4.Others |
11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Drug Stores |
11.3.4.Online Pharmacies |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12. Middle East and Africa (MEA) Branded Generics In Emerging Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Diseases Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Cardiovascular Diseases |
12.1.2.Diabetes |
12.1.3.Cancer |
12.1.4.Neurological Disorders |
12.1.5.Gastrointestinal Diseases |
12.1.6.Dermatology Diseases |
12.1.7.Others |
12.2. Route-administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oral |
12.2.2.Parenteral |
12.2.3.Topical |
12.2.4.Others |
12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Drug Stores |
12.3.4.Online Pharmacies |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13. Latin America Branded Generics In Emerging Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Diseases Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Cardiovascular Diseases |
13.1.2.Diabetes |
13.1.3.Cancer |
13.1.4.Neurological Disorders |
13.1.5.Gastrointestinal Diseases |
13.1.6.Dermatology Diseases |
13.1.7.Others |
13.2. Route-administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oral |
13.2.2.Parenteral |
13.2.3.Topical |
13.2.4.Others |
13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Drug Stores |
13.3.4.Online Pharmacies |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Abbott Laboratories (U.S.) |
14.2.2.Apotex Inc. (Canada) |
14.2.3.AstraZeneca (U.K) |
14.2.4.CSPC Pharmaceutical Group Limited. (China) |
14.2.5.Reddys Laboratories Ltd. (India) |
14.2.6.GlaxoSmithKline plc (U.K) |
14.2.7.Mylan N.V. (U.S.) |
14.2.8.Novartis AG (Switzerland) |
14.2.9.Pfizer Inc. (U.S) |
14.2.10.Sanofi (France) |
14.2.11.Sun Pharmaceutical Industries Ltd. (India) |
14.2.12.Teva Pharmaceutical Industries Ltd (Israel) |
14.2.13.Valeant Pharmaceuticals International, Inc. (Canada) |
14.2.14.Nichi-Iko Pharmaceutical Co., Ltd ( Japan) |
15. Research Methodology |
16. Appendix and Abbreviations |